Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2924764> ?p ?o }
Showing triples 1 to 79 of
79
with 100 triples per page.
- Q2924764 subject Q7081681.
- Q2924764 subject Q7334142.
- Q2924764 subject Q7400289.
- Q2924764 subject Q7486806.
- Q2924764 subject Q8275351.
- Q2924764 subject Q8388296.
- Q2924764 subject Q8616484.
- Q2924764 subject Q8965786.
- Q2924764 abstract "Brexpiprazole (/brɛksˈpɪprəzoʊl/ breks-PIP-rə-zohl; brand name Rexulti recks-UL-tee, previously known as OPC-34712) is a novel atypical antipsychotic drug. It is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). The drug received FDA approval on July 13, 2015 for the treatment of schizophrenia, and as an adjunctive treatment for depression. Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).The drug was developed by Otsuka and Lundbeck, and is considered to be a successor of Otsuka's top-selling antipsychotic agent aripiprazole (brand names: Abilify, Aripiprex). Otsuka's US patent on aripiprazole expired on October 20, 2014;however, due to a pediatric extension, a generic will become available in the near future.".
- Q2924764 atcPrefix "N05".
- Q2924764 atcSuffix "AX16".
- Q2924764 bioavailability "95.0".
- Q2924764 casNumber "913611-97-9".
- Q2924764 iupacName "7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one".
- Q2924764 pubchem "11978813".
- Q2924764 thumbnail Brexpiprazole.svg?width=300.
- Q2924764 wikiPageWikiLink Q147096.
- Q2924764 wikiPageWikiLink Q14864419.
- Q2924764 wikiPageWikiLink Q14864427.
- Q2924764 wikiPageWikiLink Q14877161.
- Q2924764 wikiPageWikiLink Q14891424.
- Q2924764 wikiPageWikiLink Q15335165.
- Q2924764 wikiPageWikiLink Q17710464.
- Q2924764 wikiPageWikiLink Q17710475.
- Q2924764 wikiPageWikiLink Q17710494.
- Q2924764 wikiPageWikiLink Q17710555.
- Q2924764 wikiPageWikiLink Q18022891.
- Q2924764 wikiPageWikiLink Q18027434.
- Q2924764 wikiPageWikiLink Q18027451.
- Q2924764 wikiPageWikiLink Q1869874.
- Q2924764 wikiPageWikiLink Q204711.
- Q2924764 wikiPageWikiLink Q21098913.
- Q2924764 wikiPageWikiLink Q238509.
- Q2924764 wikiPageWikiLink Q2419445.
- Q2924764 wikiPageWikiLink Q2938837.
- Q2924764 wikiPageWikiLink Q386378.
- Q2924764 wikiPageWikiLink Q386434.
- Q2924764 wikiPageWikiLink Q394129.
- Q2924764 wikiPageWikiLink Q407617.
- Q2924764 wikiPageWikiLink Q408471.
- Q2924764 wikiPageWikiLink Q410943.
- Q2924764 wikiPageWikiLink Q410959.
- Q2924764 wikiPageWikiLink Q41112.
- Q2924764 wikiPageWikiLink Q411188.
- Q2924764 wikiPageWikiLink Q41350.
- Q2924764 wikiPageWikiLink Q416417.
- Q2924764 wikiPageWikiLink Q416992.
- Q2924764 wikiPageWikiLink Q422244.
- Q2924764 wikiPageWikiLink Q423757.
- Q2924764 wikiPageWikiLink Q42844.
- Q2924764 wikiPageWikiLink Q4904729.
- Q2924764 wikiPageWikiLink Q600203.
- Q2924764 wikiPageWikiLink Q7081681.
- Q2924764 wikiPageWikiLink Q7334142.
- Q2924764 wikiPageWikiLink Q7400289.
- Q2924764 wikiPageWikiLink Q7486806.
- Q2924764 wikiPageWikiLink Q770260.
- Q2924764 wikiPageWikiLink Q8275351.
- Q2924764 wikiPageWikiLink Q8388296.
- Q2924764 wikiPageWikiLink Q8616484.
- Q2924764 wikiPageWikiLink Q8965786.
- Q2924764 wikiPageWikiLink Q898407.
- Q2924764 wikiPageWikiLink Q899107.
- Q2924764 wikiPageWikiLink Q902171.
- Q2924764 wikiPageWikiLink Q9368.
- Q2924764 atcPrefix "N05".
- Q2924764 atcSuffix "AX16".
- Q2924764 bioavailability "95.0".
- Q2924764 casNumber "913611".
- Q2924764 iupacName "7".
- Q2924764 pubchem "11978813".
- Q2924764 type ChemicalSubstance.
- Q2924764 type Drug.
- Q2924764 type ChemicalObject.
- Q2924764 type Thing.
- Q2924764 type Q8386.
- Q2924764 comment "Brexpiprazole (/brɛksˈpɪprəzoʊl/ breks-PIP-rə-zohl; brand name Rexulti recks-UL-tee, previously known as OPC-34712) is a novel atypical antipsychotic drug. It is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). The drug received FDA approval on July 13, 2015 for the treatment of schizophrenia, and as an adjunctive treatment for depression.".
- Q2924764 label "Brexpiprazole".
- Q2924764 depiction Brexpiprazole.svg.